Today: 9 June 2026
ST Engineering (S63) share price drops in Singapore trade as Airshow 2026 nears, FY2025 results loom
20 January 2026
1 min read

ST Engineering (S63) share price drops in Singapore trade as Airshow 2026 nears, FY2025 results loom

Singapore, Jan 20, 2026, 15:33 SGT — Regular session

  • ST Engineering shares dipped roughly 1.3% in afternoon trading, following Monday’s close at S$9.64.
  • Traders noted a technical pullback following the stock’s surge toward the S$10 level late last year.
  • Attention turns to the Singapore Airshow, running Feb 3-8, along with the upcoming FY2025 results period for the company.

Shares of Singapore Technologies Engineering Ltd slipped 1.3% to S$9.51 by mid-afternoon Tuesday, down from Monday’s close of S$9.64, data from Investing.com shows. The stock has oscillated between S$9.51 and S$9.64 during the session and remains just shy of its 52-week peak at S$9.69. It’s still trading above Investing.com’s average analyst target of roughly S$9.20.

The dip is notable since ST Engineering has stood out among Singapore’s blue chips lately, buoyed by defence-linked stocks attracting buyers amid ongoing global security worries.

At this stage, even minor shifts can seem amplified. A quick dip might shake out late buyers, particularly with earnings and event risks looming close.

Gerald Wong from Beansprout noted in a Monday market update that ST Engineering is pushing its 2025 gains closer to the S$10.00 mark. He also flagged that certain indicators appear stretched following this rally.

The next key event is the Singapore Airshow, set for Feb. 3-8 at Changi Exhibition Centre. Aerospace and defense suppliers typically seize the opportunity to schedule meetings and unveil new projects during the week.

In a Dec. 30 update, the company said it anticipates posting a positive net profit for the second half of 2025, factoring in “all the one-off effects” during that timeframe. https://www.stengg.com/en/newsroom/news-re…

The longer-term bull case still hinges on backlog. On Nov. 12, ST Engineering reported its order book reached S$32.6 billion at the end of September 2025, boosted by S$14.0 billion in contract wins during the first nine months of 2025.

Investors remain fixated on a significant risk: ST Engineering took a S$667 million non-cash impairment charge on its iDirect group last November and is now weighing strategic options for that unit.

Traders are eyeing if the stock can stay above today’s low around S$9.51 and push back above Monday’s closing price. The spotlight will then shift to the FY2025 earnings release, set for Feb. 26, according to TradingView’s earnings calendar.

Stock Market Today

  • S&P 500 Rallies on Chipmaker Gains; Crude Oil Prices Retreat After Iran-Israel Ceasefire Signal
    June 9, 2026, 9:24 AM EDT. The S&P 500 gained +0.30% on Monday, driven by renewed investor interest in artificial intelligence boosting chipmakers. Nasdaq 100 rose +1.58%, while the Dow slipped -0.16%, dragged lower by Apple's -1% drop amid lukewarm AI platform feedback. Crude oil prices surged over +4% initially due to Iran-Israel tensions but retreated after Iran signaled an end to its current military operation. The market discounts a low 3% chance of a +25 basis point rate hike by the Federal Reserve on June 16-17. Treasury yields climbed, with 10-year notes reaching a two-week high of 4.58%, pressured by strong US jobs data and heavy upcoming Treasury auctions. Overseas markets closed mixed, with China's Shanghai Composite down -1.70% and Japan's Nikkei falling -3.85%.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
DBS share price dips after CGS downgrade, with Feb. 9 results the next test
Previous Story

DBS share price dips after CGS downgrade, with Feb. 9 results the next test

OpenAI CFO Sarah Friar lifts lid on $20B revenue run rate as 2026 shifts to “practical adoption”
Next Story

OpenAI CFO Sarah Friar lifts lid on $20B revenue run rate as 2026 shifts to “practical adoption”

Go toTop